

REFERENCES

1. Eisner MD, Anthonisen N, Coultas D: An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 182: 693, 2010. [PMID: 20802169]
2. <https://www.nice.org.uk/guidance/indevelopment/gid-ng10115/documents> (National Institute for Health and Care Excellence: Chronic obstructive pulmonary disease [acute exacerbation]: antimicrobial prescribing, July 2018.) Accessed on November 15, 2018.
3. Qaseem A, Wilt TJ, Weinberger SE, et al: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. *Ann Intern Med* 155: 179, 2011. [PMID: 21810710]
4. O'Donnell DE, Aaron S, Bourbeau J, et al: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. *Can Respir J* 14(Suppl B): 5B, 2007. [PMID: 17885691]
5. <http://www.copdx.org.au/> (Abramson M, Crockett AJ, Dabscheck E: The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease V2.36, 2013.) Accessed September 23, 2014.
6. <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf> (Global Initiative for Chronic Obstructive Lung Disease [GOLD]: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2019 report.) Accessed on November 21, 2018.
7. Lamprecht B, Soriano JB, Studnicka M, et al: Determinants of underdiagnosis of COPD in national and international surveys. *Chest* 148: 971, 2015. [PMID: 25950276]
8. Gariani K, Delabava A, Perneger TV, et al: Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. *Swiss Med Wkly* 141: w13298, 2011. [PMID: 22072300]
9. Calverley PM, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 356: 775, 2007. [PMID: 17314337]
10. Vogelmeier C, Kardos P, Harari S, et al: Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. *Respir Med* 102: 1511, 2008. [PMID: 18804362]
11. Jones PW, Singh D, Bateman ED, et al: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. *Eur Respir J* 40: 830, 2012. [PMID: 22441743]
12. Vogelmeier CF, Bateman ED, Pallante J, et al: Efficacy and safety of once-daily QVA 149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomized, double blind, parallel group study. *Lancet Respir Med* 1: 51, 2013. [PMID: 24321804]
13. Wood-Baker R, Walters J, Walters EH: Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. *Respir Med* 101: 371, 2007. [PMID: 16962307]
14. Criner GJ, Connett JE, Aaron SD, et al: Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. *N Engl J Med* 370: 2201, 2014. [PMID: 24836125]
15. Han MK, Tayob N, Murray S: Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. *Am J Respir Crit Care Med* 189: 1503, 2014. [PMID: 24779680]
16. Bernstein SL, Boudreaux ED, Cabral L: Efficacy of a brief intervention to improve emergency physicians' smoking cessation counseling skills, knowledge, and attitudes. *Subst Abus* 30: 158, 2009. [PMID: 19347755]
17. Tonnesen P: Smoking cessation and COPD. *Eur Respir Rev* 22: 37, 2013. [PMID: 23457163]
18. Celli BR, Barnes PJ: Exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 29: 1224, 2007. [PMID: 17540785]
19. Barker BL, Haldar K, Patel H, et al: Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. *Chest* 147: 46, 2015. [PMID: 25103335]
20. Rangelov K, Sethi S: Role of infections. *Clin Chest Med* 35: 87, 2014. [PMID: 24507839]
21. Terada K, Muro S, Sato S, et al: Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. *Thorax* 63: 951, 2008. [PMID: 18535116]
22. Baumeler L, Papakonstantinou E, Milenkovic B, et al: Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. *Respirology* 21: 883, 2016. [PMID: 26970108]
23. Kent BD, Mitchell PD, McNicholas WT: Hypoxemia in patients with COPD: cause, effects, and disease progression. *Int J Chron Obstruct Pulm Dis* 6: 199, 2011. [PMID: 21660297]
24. Wollenweider DJ, Jarrett H, Steurer-Stey CA, et al: Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 12: CD010257, 2012. [PMID: 23235687]
25. McKeever TM, Hearson G, Housley G, et al: Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study. *Thorax* 71: 210, 2016. [PMID: 26628461]
26. Emerman CL, Lukens TW, Effron D: Physician estimation of FEV1 in acute exacerbation of COPD. *Chest* 105: 1709, 1994. [PMID: 7911418]
27. Anthonisen NR, Manfreda J, Warren CP, et al: Antibiotic therapy in exacerbations of COPD. *Ann Intern Med* 106: 196, 1987. [PMID: 3492164]
28. Emerman CL, Cydulka RK: Evaluation of high-yield criteria for chest radiography in acute exacerbation of chronic obstructive pulmonary disease. *Ann Emerg Med* 22: 680, 1993. [PMID: 8457095]
29. Austin MA, Wills KE, Blizzard L, et al: Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. *BMJ* 341: c5462, 2010. [PMID: 20959284]
30. Emerman CL, Cydulka RK: Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. *Ann Emerg Med* 29: 474, 1997. [PMID: 9095007]
31. Edwards L, Perrin K, Williams M, et al: Randomised controlled crossover trial of the effect on PtCO₂ of oxygen-driven versus air-driven nebulisers in severe chronic obstructive pulmonary disease. *Emerg Med J* 29: 894, 2012. [PMID: 22158529]
32. Leuppi JD, Schuetz P, Bingisser R, et al: Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. *JAMA* 309: 2223, 2013. [PMID: 23695200]
33. Gallego M, Pomares X, Espasa M, et al: *Pseudomonas aeruginosa* isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. *BMC Pulm Med* 14: 103, 2014. [PMID: 24964956]
34. Burns K, Meade MO, Premji A, et al: Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure. *Cochrane Database Syst Rev* 12: CD004127, 2013. [PMID: 24323843]
35. Jeppesen E, Brurberg KG, Vist GE, et al: Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 5: CD003573, 2012. [PMID: 22592692]
36. Kim S, Emerman CE, Cydulka RK, et al: Prospective multicenter study of relapse following treatment for asthma/COPD among adults presenting to the emergency department. *Acad Emerg Med* 8: 533, 2001.
37. Rowe BH, Voaklander DC, Narrie TJ, et al: Outcomes following chronic obstructive pulmonary disease presentations to emergency departments in Alberta: a population-based study. *Can Respir J* 17: 295, 2010. [PMID: 21165352]
38. Goksu E, Oktay C, Kartal M, et al: Factors affecting revisit of COPD exacerbated patients presenting to emergency department. *Eur J Emerg Med* 17: 283, 2010. [PMID: 19829119]